TriSalus Life Sciences (NASDAQ: TLSI) has initiated patient enrollment for its PREDICTT clinical trial designed to evaluate its novel Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic liver tumors.
The PREDICTT trial is an investigator-led single-arm, prospective, interventional study designed to evaluate how PEDD impacts tumor targeting and radiation dose distribution. Investigators at The University of Texas MD Anderson Cancer Center will assess the use of the company’s FDA-cleared TriNav Infusion System in conjunction with Y90 radioembolization therapy.
In a statement, Richard Marshall, MD, CMO at TriSalus, commented, “This study represents an important step toward optimizing locoregional therapies through advanced delivery technologies. We are proud to collaborate with UT MD Anderson to generate clinical evidence that could redefine how Y90 therapies are delivered.”
